June 09, 2026 04:00 ET | Source: Royal Philips June 9, 2026 Amsterdam, the Netherlands – AI is already saving clinicians the equivalent of over 16 working days a year and helping them see more patients, but healthcare systems risk falling behind because of inadequate training and fragmented infrastructure. That’s according to findings from Philips’ Future Health Index
June 08, 2026 13:23 ET | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed
June 08, 2026 13:15 ET | Source: Vantive GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) — Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized
June 08, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO® and AUSTEDO XR®. The
June 07, 2026 14:30 ET | Source: Boehringer Ingelheim Limited Ingelheim, Germany – Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without
June 05, 2026 11:48 ET | Source: EnGeneIC SYDNEY and NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — EnGeneIC Limited today announced it has been recognized with the Breakthrough in glioblastoma Biotech Award 2026 at the Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event in New York City. The award was presented to Joint-CEO’s and
June 05, 2026 11:30 ET | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life
June 05, 2026 04:30 ET | Source: Vantive New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis Findings highlight the importance of coordinated, patient-centric kidney care, including early referral,
June 04, 2026 08:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea®, in Europe further strengthening the Company’s growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva’s strategy to build a leading biosimilars business in
June 04, 2026 04:00 ET | Source: Royal Philips June 4, 2026 Seven-year collaboration puts WellSpan at the forefront of diagnostics and imaging in community health through a groundbreaking research and innovation strategy aimed at shaping the future of care delivery Amsterdam and YORK, Pa. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,
June 03, 2026 16:05 ET | Source: Iovance Biotherapeutics, Inc. First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering
June 03, 2026 07:00 ET | Source: Dark Horse Consulting Group WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing
New collaboration delivers the POCUS Fundamentals Certificate to clinicians worldwide, creating a structured entry point for point-of-care ultrasound training. June 03, 2026 00:40 ET | Source: Inteleos, Inc. ROCKVILLE, Md. and HYDERABAD, India, June 03, 2026 (GLOBE NEWSWIRE) — The Point-of-Care Ultrasound (POCUS) Certification Academy, part of Inteleos, is partnering with Medvarsity to expand global access to
June 02, 2026 14:43 ET | Source: Alamar Biosciences, Inc. NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices Workflow extends NULISA into longitudinal, decentralized, and population-scale research FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in
June 02, 2026 09:00 ET | Source: Royal Philips June 2, 2026 Philips receives FDA 510(k) clearance for Elevate Plus for EPIQ Elite and Affiniti, delivering AI advancements in general imaging ultrasound AI-powered workflow automation helps clinicians acquire high-quality reproducible images faster and with greater confidence Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
